SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-027552
Filing Date
2023-08-10
Accepted
2023-08-10 16:16:11
Documents
78
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1082580
2 ex31-1.htm EX-31.1 18065
3 ex31-2.htm EX-31.2 18039
4 ex32-1.htm EX-32.1 9905
  Complete submission text file 0001493152-23-027552.txt   6533163

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE lctx-20230630.xsd EX-101.SCH 54177
6 XBRL CALCULATION FILE lctx-20230630_cal.xml EX-101.CAL 67121
7 XBRL DEFINITION FILE lctx-20230630_def.xml EX-101.DEF 200092
8 XBRL LABEL FILE lctx-20230630_lab.xml EX-101.LAB 404772
9 XBRL PRESENTATION FILE lctx-20230630_pre.xml EX-101.PRE 315133
72 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1120830
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12830 | Film No.: 231159699
SIC: 2836 Biological Products, (No Diagnostic Substances)